Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Cytokine therapy can activate potent, sustained antitumor responses, but collateral toxicity often limits dosages. Although antibody–cytokine fusions (immunocytokines) have been designed with the intent to localize cytokine activity, systemic dose-limiting side effects are not fully ameliorated by a...
| Main Authors: | , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2015
|
| Online Access: | http://hdl.handle.net/1721.1/98398 https://orcid.org/0000-0003-2398-5896 https://orcid.org/0000-0001-7316-6923 https://orcid.org/0000-0002-9851-7029 |